<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01266421</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2010_03</org_study_id>
    <nct_id>NCT01266421</nct_id>
  </id_info>
  <brief_title>Visanne Post-approval Observational Study (VIPOS)</brief_title>
  <official_title>International Active Surveillance Study of Medication Used for the Treatment of Endometriosis: Visanne Post-approval Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study assesses safety aspects of Dienogest (DNG) 2mg/day (Visanne) used as endometriosis&#xD;
      therapy and of other hormonal treatments for endometriosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a common, chronic, gynecological disease characterized by pain and impaired&#xD;
      fertility. It causes chronic inflammation, ovarian cyst formation, fibrosis and adhesions.&#xD;
      Symptoms seem to respond to decreased circulating estrogen. The mainstay of medical treatment&#xD;
      is hormonal induced anovulation and a reduction in endogenous estrogen production.&#xD;
&#xD;
      Medications for endometriosis such as Danazol and GnRH agonists have clinically relevant&#xD;
      side-effects limiting treatment duration with these medications to 6-12 months.&#xD;
&#xD;
      Dienogest (DNG) is a 19-nortestosterone derivative progestogen. DNG 2mg/day is a reliable and&#xD;
      effective treatment for dysmenorrhea, premenstrual pain, dyspareunia and diffuse pelvic pain&#xD;
      associated with endometriosis.&#xD;
&#xD;
      Two important class effects of progestogens are the induction of bleeding disturbances and&#xD;
      their influence on mood disturbance. It is not known what influence DNG will have on bleeding&#xD;
      disturbances associated with endometriosis, particularly over a longer time frame.&#xD;
&#xD;
      In addition, women who suffer from endometriosis are at high risk of developing depressive&#xD;
      symptoms. It is difficult to differentiate if depressive symptoms are causally associated&#xD;
      with progestogen use or sequela of the disease process.&#xD;
&#xD;
      This study investigates the safety of DNG for endometriosis with regard to medical&#xD;
      interventions for anemia and worsening of depressive symptoms associated with the disease. It&#xD;
      is a prospective, controlled, non-interventional cohort study with two cohorts: users of DNG&#xD;
      and users of other medications for the treatment of endometriosis. The study will be&#xD;
      implemented in several European countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 7, 2010</start_date>
  <completion_date type="Actual">January 26, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Anemia</measure>
    <time_frame>Within 6 years</time_frame>
    <description>Medical intervention for anemia induced by cyclical bleeding disturbances (anemia)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Depression</measure>
    <time_frame>Within 6 years</time_frame>
    <description>First time occurence of clinically relevant depression, or worsening of existing depression</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">27840</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>Dienogest (DNG)</arm_group_label>
    <description>Women using DNG) for the treatment of endometriosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Other approved endometriosis drugs (OAED)</arm_group_label>
    <description>Women using hormonal medications approved for endometriosis treatment in all particiapting countries other than DNG.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-approved endometriosis drugs (NAED)</arm_group_label>
    <description>Women using hormonal medications not approved for endometriosis treatment in all particiapting countries.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using medications for the treatment of endometriosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women using a newly prescribed regimen for endometriosis (first-time users or&#xD;
             switchers or re-starters)&#xD;
&#xD;
          -  Women who are willing to participate in this long-term follow-up study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are not cooperative/available for follow-up&#xD;
&#xD;
          -  Women with a language barrier&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaas Heinemann, PhD, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research</name>
      <address>
        <city>Berlin</city>
        <zip>10115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Moehner S, Becker K, Lange JA, von Stockum S, Heinemann K. Risk of depression and anemia in users of hormonal endometriosis treatments: Results from the VIPOS study. Eur J Obstet Gynecol Reprod Biol. 2020 Aug;251:212-217. doi: 10.1016/j.ejogrb.2020.05.049. Epub 2020 Jun 2.</citation>
    <PMID>32559605</PMID>
  </results_reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2010</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Center for Epidemiology and Health Research, Germany</investigator_affiliation>
    <investigator_full_name>Klaas Heinemann, MD, PhD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>DNG</keyword>
  <keyword>Anemia</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 21, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01266421/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT01266421/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

